News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Salvador Jaime-Casas: Incidental Pathogenic Variants in Renal Cell and Urothelial Carcinoma
Photo from Salvador Jaime-Casas/X
Aug 4, 2024, 12:29

Salvador Jaime-Casas: Incidental Pathogenic Variants in Renal Cell and Urothelial Carcinoma

Salvador Jaime-Casas, Postdoc Fellow at City of Hope, posted on X about a recent paper titled “Incidental Pathogenic Variants in Renal Cell and Urothelial Carcinoma: Is It Time for Universal Screening?” published on JCO Precision Oncology.

Authors: Salvador Jaime-Casas, Wesley Yip and Joanne M. Jeter

Image

“Thrilled to share our latest pub in JCO Precision Oncology ‘Incidental Pathogenic Variants in Renal Cell and Urothelial Carcinoma: Is It Time for Universal Screening?’ Immensely grateful for my mentor’s Wesley Yip guidance throughout this journey.”

Source: Salvador Jaime-Casas/X

cancer City of Hope JCO Precision Oncology Joanne M. Jeter OncoDaily Oncology Salvador Jaime-Casas urothelial carcinoma Wesley Yip
Special Coverage
Insight
Dec 21, 2024, 10:35
30 Years of Leadership in Immuno-Oncology - Agenus
Blog
Dec 21, 2024, 10:19
A Portrait of Germline Pathogenic Variants in Breast Cancer Genes in Brazil
Dialogues
Dec 21, 2024, 10:09
Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market
Blog
Dec 21, 2024, 09:22
When the world of science and sports comes together! - The V Foundation
Blog
Dec 21, 2024, 09:16
Timely cancer treatment isn’t just a goal, It’s a necessity - European Cancer Organisation
Science
Dec 21, 2024, 09:06
Toni Choueiri: The Final Analysis of the JAVELIN Renal 101 trial
Blog
Dec 21, 2024, 09:00
Miriam Mutebi: Does Nipple and Areola Size Matter?
Science
Dec 21, 2024, 08:51
Wafik S. El-Deiry: Our recent review on Targeting the SMURF2-HIF1α axis
Science
Dec 21, 2024, 08:48
Oncology Brothers: Another ALK inhibitor gets FDA approval
Science
Dec 21, 2024, 08:42
Eric K. Singhi: Decoding clinical trial jargon
Science
Dec 21, 2024, 08:37
Gustavo Viani: The Role of Radiotherapy on the management of HCC
Science
Dec 21, 2024, 08:29
Bishal Gyawali: The case of cancer drug Xtandi